PolyPid (PYPD) Competitors $3.27 -0.08 (-2.39%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.24 -0.03 (-0.95%) As of 10/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. NYXH, ELMD, SKIN, KRMD, INFU, STIM, PROF, SGHT, AVR, and LAKEShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Nyxoah (NYXH), Electromed (ELMD), Beauty Health (SKIN), KORU Medical Systems (KRMD), InfuSystem (INFU), Neuronetics (STIM), Profound Medical (PROF), Sight Sciences (SGHT), Anteris Technologies Global (AVR), and Lakeland Industries (LAKE). These companies are all part of the "medical equipment" industry. PolyPid vs. Its Competitors Nyxoah Electromed Beauty Health KORU Medical Systems InfuSystem Neuronetics Profound Medical Sight Sciences Anteris Technologies Global Lakeland Industries Nyxoah (NASDAQ:NYXH) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk. Does the media prefer NYXH or PYPD? In the previous week, Nyxoah and Nyxoah both had 1 articles in the media. PolyPid's average media sentiment score of 1.00 beat Nyxoah's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media. Company Overall Sentiment Nyxoah Neutral PolyPid Positive Do institutionals and insiders believe in NYXH or PYPD? 26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is NYXH or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Nyxoah's net margin of -1,541.84%. Nyxoah's return on equity of -79.18% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Nyxoah-1,541.84% -79.18% -54.92% PolyPid N/A -453.95%-138.92% Do analysts prefer NYXH or PYPD? Nyxoah presently has a consensus price target of $15.00, indicating a potential upside of 158.62%. PolyPid has a consensus price target of $12.40, indicating a potential upside of 279.20%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Nyxoah.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50PolyPid 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has preferable earnings and valuation, NYXH or PYPD? PolyPid has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNyxoah$4.89M40.40-$64.10M-$2.30-2.52PolyPidN/AN/A-$29.02M-$3.83-0.85 Which has more risk and volatility, NYXH or PYPD? Nyxoah has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. SummaryPolyPid beats Nyxoah on 10 of the 15 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.99M$2.62B$6.13B$10.55BDividend YieldN/A57.79%5.72%4.83%P/E Ratio-0.8523.3185.7827.06Price / SalesN/A778.09612.92132.30Price / CashN/A27.2425.8230.35Price / Book4.365.3212.226.58Net Income-$29.02M$33.06M$3.33B$276.84M7 Day Performance-2.10%-0.91%0.67%-0.72%1 Month Performance-5.22%7.35%6.88%2.16%1 Year Performance-8.91%-5.13%58.88%34.63% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid3.4213 of 5 stars$3.27-2.4%$12.40+279.2%-8.9%$51.99MN/A-0.8580Positive NewsShort Interest ↓Gap DownNYXHNyxoah2.2767 of 5 stars$6.12-2.7%$15.00+145.1%-39.1%$208.45M$4.89M-2.66110Gap UpELMDElectromed3.3866 of 5 stars$24.54-0.1%$36.25+47.7%+5.2%$206.13M$64M32.81160SKINBeauty Health2.1293 of 5 stars$1.54+1.0%$2.81+83.2%-10.6%$194.67M$334.30M-5.481,030KRMDKORU Medical Systems1.1435 of 5 stars$4.09+0.5%$4.63+13.1%+55.2%$188.89M$33.65M-45.3980News CoverageINFUInfuSystem3.9656 of 5 stars$9.13-1.0%$13.50+47.9%+28.2%$186.39M$139.89M152.11410Positive NewsShort Interest ↑STIMNeuronetics1.7204 of 5 stars$2.73-1.3%$7.00+156.9%+177.1%$180.18M$74.89M-2.41180PROFProfound Medical1.6379 of 5 stars$5.83-2.5%$11.00+88.6%-28.6%$176.96M$10.68M-4.02150SGHTSight Sciences1.4795 of 5 stars$3.27+0.4%$4.33+32.4%-21.4%$170.67M$79.87M-3.39210Gap UpAVRAnteris Technologies Global1.7812 of 5 stars$4.44-0.2%$16.50+271.6%N/A$160.11M$2.70M0.00138Short Interest ↑Gap DownLAKELakeland Industries4.2631 of 5 stars$16.35+1.3%$25.00+52.9%-23.0%$155.70M$167.21M-5.942,100 Related Companies and Tools Related Companies Nyxoah Alternatives Electromed Alternatives Beauty Health Alternatives KORU Medical Systems Alternatives InfuSystem Alternatives Neuronetics Alternatives Profound Medical Alternatives Sight Sciences Alternatives Anteris Technologies Global Alternatives Lakeland Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
